読み込み中
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
前日終値
$0.6056
−$0.0034 · -0.56%
時間外
$0.669
+$0.0634 · +10.47%
10月9日 19:45 ET
日中の時刻はETです。市場データは遅延する場合があります。
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
日中レンジ
現在 $0.6056
52週レンジ
現在 $0.6056
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
30
割高
センチメント
53
まちまち
リスク
65
高リスク
モメンタム
33
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
日中レンジ
現在 $0.6056
52週レンジ
現在 $0.6056
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | — | 135.1万 USD | 135.1万 USD |
| 売上原価 | 8.7万 USD | — | 30.2万 USD | — | — |
| 粗利益 | −8.7万 USD | — | −30.2万 USD | 135.1万 USD | 135.1万 USD |
| 研究開発 | 438.8万 USD | 264.4万 USD | 727.2万 USD | 2558.2万 USD | 3688.8万 USD |
| 販売・一般管理 | 455.7万 USD | 611万 USD | 750.7万 USD | 1300.8万 USD | 3070.3万 USD |
| 営業費用 | 885.8万 USD | 875.4万 USD | 1477.9万 USD | 3859万 USD | 6759.1万 USD |
| 受取利息 | 7.8万 USD | 5.9万 USD | 42.1万 USD | 19.5万 USD | 9.8万 USD |
| 支払利息 | — | — | — | 1.7万 USD | 8.7万 USD |
| 減価償却費と償却費 | 8.7万 USD | 28.5万 USD | 30.2万 USD | 23.2万 USD | 6.1万 USD |
| 営業利益 | −894.5万 USD | −875.4万 USD | −1508.1万 USD | −3723.9万 USD | −6624万 USD |
| 純利益 | −799.2万 USD | −1112.3万 USD | −2102.6万 USD | −3327.9万 USD | −6417.9万 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
